Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PTHN

Patheon N.V. Ordinary shares, p (PTHN) Stock Price, News & Analysis

Patheon N.V. Ordinary shares, p logo

About Patheon N.V. Ordinary shares, p Stock (NYSE:PTHN)

Advanced Chart

Key Stats

Today's Range
$34.98
$34.98
50-Day Range
N/A
52-Week Range
$23.72
$35.13
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive PTHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patheon N.V. Ordinary shares, p and its competitors with MarketBeat's FREE daily newsletter.

PTHN Stock News Headlines

Lilium N.V - Ordinary Shares - Class A
Robinhood Markets Inc - Ordinary Shares - Class A
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Immatics NV Ordinary Shares
CTP NV Ordinary Shares
Lilium NV Ordinary Shares - Class A LILM
See More Headlines

PTHN Stock Analysis - Frequently Asked Questions

Patheon N.V. Ordinary shares, p (NYSE:PTHN) issued its quarterly earnings data on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. The company's quarterly revenue was up 3.2% compared to the same quarter last year.

Patheon N.V. Ordinary shares, p (PTHN) raised $625 million in an initial public offering on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Patheon N.V. Ordinary shares, p investors own include SVB Financial Group (SIVPQ), Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Alexion Pharmaceuticals (ALXN), NXP Semiconductors (NXPI), Bank of the Ozarks (OZRK) and Coherus BioSciences (CHRS).

Company Calendar

Last Earnings
6/08/2017
Today
6/09/2025
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:PTHN
Previous Symbol
NASDAQ:PTHN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NYSE:PTHN) was last updated on 6/9/2025 by MarketBeat.com Staff
From Our Partners